Nls pharmaceutics and kadimastem announces up to $3 million equity financing and $25 million equity facility agreement

The equity financing is at a 10% premium to the market share price1 zÜrich, switzerland / access newswire / march 31, 2025 / nls pharmaceutics ltd. (nasdaq:nlsp) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (cns) disorders, today announced the closing of a $2 million equity financing of preferred shares at a stated value of $1.65 per share, with a potential second closing of up to an additional $1 million of preferred shares at a purchase price of $1.65 per share.
NLSP Ratings Summary
NLSP Quant Ranking